Here’s a structured collection of FAQs tailored for academic researchers working with MED25 antibodies, incorporating methodological insights and data from diverse sources:
Methodological Answer:
Positive/Negative Controls: Use lysates from tissues/cell lines with confirmed MED25 expression (e.g., human spleen, brain) and knockout models .
Blocking Peptide Assays: Pre-incubate antibodies with recombinant MED25 immunogen to confirm signal loss .
Cross-Reactivity Checks: Validate across species (human, mouse, rat) using comparative WB .
| Validation Parameter | Recommended Approach | Source |
|---|---|---|
| WB Specificity | Lysates from HEK293 (high MED25) | |
| IF Specificity | Knockout cell lines + siRNA | |
| Species Reactivity | Parallel testing in human/mouse |
Methodological Answer:
Western Blot: Start with 1:500–1:2000 dilution in 5% non-fat milk .
IF/ICC: Use 1:50–1:200 dilution with Triton X-100 permeabilization .
Fixation: 4% paraformaldehyde for 15 min, followed by antigen retrieval in citrate buffer (pH 6.0) .
Methodological Answer:
Interaction Studies: Use co-immunoprecipitation (co-IP) with MYC2 or ABI5 transcription factors in Arabidopsis .
Chromatin Studies: Sequential ChIP-qPCR to detect MED25 and COI1 enrichment on JAZ8 or ERF1 promoters .
| Target Pathway | Key Partners | Technique | Source |
|---|---|---|---|
| JA Signaling | MYC2, COI1 | Co-IP + ChIP-qPCR | |
| ABA Signaling | ABI5 | Y2H + Luciferase |
Methodological Answer:
Domain Mapping: Test MED25 truncations (e.g., ACID domain) in yeast two-hybrid (Y2H) assays with ABI5 .
Mutant Analysis: Compare med25-4 and myc2-2 mutants using qRT-PCR for PDF1.2 and ERF1 expression under ABA/JA treatments .
| Observation | Resolution Strategy | Source |
|---|---|---|
| MED25 represses ABA-responsive genes | Use med25-4 mutants + ABI5 co-IP |
Isoform-Specific WB: Use NuPAGE gels (4–12% Bis-Tris) to resolve ~75–80 kDa bands .
siRNA Knockdown: Target exon junctions unique to specific isoforms (e.g., isoforms 1–5) .
Example Issue: Discrepancies in MED25’s role in JA vs. ABA pathways.
Resolution Workflow: